DOP2010000327A - Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento de nivel de creatinina debido a la administracion de dronedarona - Google Patents
Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento de nivel de creatinina debido a la administracion de dronedaronaInfo
- Publication number
- DOP2010000327A DOP2010000327A DO2010000327A DO2010000327A DOP2010000327A DO P2010000327 A DOP2010000327 A DO P2010000327A DO 2010000327 A DO2010000327 A DO 2010000327A DO 2010000327 A DO2010000327 A DO 2010000327A DO P2010000327 A DOP2010000327 A DO P2010000327A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- dronedarona
- patients
- arritmia
- administration
- prepare
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
UTILIZACION DE DRONEDARONA O UNA DE SUS SALES ACEPTABLES FARMACEUTICAMENTE PARA PREPARAR UN MEDICAMENTO PARA EL TRATAMIENTO DE PACIENTES CON ARRITMIA, TENIENDO DICHOS PACIENTES UN INCREMENTO EN EL NIVEL DE CREATININA DEBIDO A LA ADMINISTRACION DE DRONEDARONA, INCREMENTANDOSE DICHO NIVEL DE CREATININA DESPUES DEL INICIO DEL TRATAMIENTO CON DRONEDARONA, ALCANZANDO DICHO INCREMENTO DEL NIVEL DE CREATININA UN PLATO Y UTILIZANDOSE COMO UNA LINEA BASE NUEVA, SIENDO DICHO INCREMENTO DEL NIVEL DE CREATININA REVERSIBLE DESPUES DE LA SUSPENSION DE LA DRONEDARONA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4873208P | 2008-04-28 | 2008-04-28 | |
EP08290407A EP2116239A1 (en) | 2008-04-29 | 2008-04-29 | Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2010000327A true DOP2010000327A (es) | 2011-01-31 |
Family
ID=39680951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2010000327A DOP2010000327A (es) | 2008-04-28 | 2010-10-28 | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento de nivel de creatinina debido a la administracion de dronedarona |
Country Status (27)
Country | Link |
---|---|
US (1) | US20100016423A1 (es) |
EP (2) | EP2116239A1 (es) |
JP (1) | JP2011518872A (es) |
KR (1) | KR20100135853A (es) |
CN (1) | CN102076337A (es) |
AR (1) | AR072954A1 (es) |
AU (1) | AU2009241286A1 (es) |
BR (1) | BRPI0912706A2 (es) |
CA (1) | CA2722815A1 (es) |
CL (1) | CL2009001018A1 (es) |
CO (1) | CO6311076A2 (es) |
DO (1) | DOP2010000327A (es) |
EA (1) | EA201071138A1 (es) |
EC (1) | ECSP10010567A (es) |
IL (1) | IL208900A0 (es) |
MA (1) | MA32299B1 (es) |
MX (1) | MX2010011873A (es) |
NI (1) | NI201000181A (es) |
NZ (1) | NZ588886A (es) |
PA (1) | PA8824601A1 (es) |
PE (1) | PE20091885A1 (es) |
SG (1) | SG188180A1 (es) |
TW (1) | TW200948355A (es) |
UA (1) | UA100883C2 (es) |
UY (1) | UY31790A (es) |
WO (1) | WO2009133470A2 (es) |
ZA (1) | ZA201007727B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2280701A2 (en) | 2008-04-17 | 2011-02-09 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
FR2930149B1 (fr) * | 2008-04-17 | 2011-02-18 | Sanofi Aventis | Association de dronedarone avec au moins un diuretique, son application en therapeutique |
FR2959132A1 (fr) * | 2010-04-22 | 2011-10-28 | Sanofi Aventis | Procedes pour l'evaluation et la reduction des risques |
US8602215B2 (en) | 2010-06-30 | 2013-12-10 | Sanofi | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
WO2012023024A2 (en) * | 2010-08-17 | 2012-02-23 | Lupin Limited | Controlled release formulations of dronedarone |
RU2456019C1 (ru) * | 2011-03-29 | 2012-07-20 | Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" | Способ прогнозирования развития жизнеопасных желудочковых аритмий у пациентов без структурных изменений сердца |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4868179A (en) * | 1987-04-22 | 1989-09-19 | Cohn Jay N | Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate |
FR2665444B1 (fr) * | 1990-08-06 | 1992-11-27 | Sanofi Sa | Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant. |
FR2735365B1 (fr) * | 1995-06-14 | 1997-09-05 | Sanofi Sa | Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires |
FR2746013B1 (fr) * | 1996-03-18 | 1998-05-29 | Sanofi Sa | Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus |
FR2764800B1 (fr) * | 1997-06-23 | 1999-09-10 | Sanofi Sa | Composition pharmaceutique solide contenant des derives de benzofuranne |
US6897305B2 (en) * | 1998-06-08 | 2005-05-24 | Theravance, Inc. | Calcium channel drugs and uses |
CN1330556A (zh) * | 1998-11-06 | 2002-01-09 | G·D·西尔公司 | 血管紧张肽-转化酶抑制剂和醛固酮拮抗剂用于降低心血管疾病的发病率和死亡率的联合疗法 |
US20030113330A1 (en) * | 1999-11-08 | 2003-06-19 | Uhal Bruce D. | Methods for treating pulmonary fibrosis |
US6411840B1 (en) * | 1999-11-16 | 2002-06-25 | Cardiac Intelligence Corporation | Automated collection and analysis patient care system and method for diagnosing and monitoring the outcomes of atrial fibrillation |
FR2803846B1 (fr) * | 2000-01-17 | 2002-04-05 | Clariant France Sa | 3-(1-hydroxy-pentylidene)-5-nitro-3h-benzofuran-2-one, son procede de preparation et son utilisation |
GB0020691D0 (en) * | 2000-08-22 | 2000-10-11 | Boehringer Ingelheim Pharma | Pharmaceutical combination |
FR2817864B1 (fr) * | 2000-12-11 | 2003-02-21 | Sanofi Synthelabo | Derive de methanesulfonamido-benzofurane, son procede de preparation et son utilisation comme intermediaire de synthese |
FR2817865B1 (fr) * | 2000-12-11 | 2005-02-18 | Sanofi Synthelabo | Derive aminoalkoxybenzoyle sous forme de sel, son procede de preparation et son utilisation comme intermediaire de synthese |
FR2817750B1 (fr) * | 2000-12-11 | 2003-02-21 | Sanofi Synthelabo | Composition pharmaceutique de dronedarone pour administration parenterale |
EP1347756B1 (en) * | 2000-12-27 | 2006-03-08 | Genzyme Corporation | Controlled release of anti-arrhythmic agents from a biodegradable hydrogel for local application to the heart |
US6831102B2 (en) * | 2001-12-07 | 2004-12-14 | Bristol-Myers Squibb Company | Phenyl naphthol ligands for thyroid hormone receptor |
US20030229007A1 (en) * | 2002-05-30 | 2003-12-11 | Roberto Levi | Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia |
DE10237819A1 (de) * | 2002-08-19 | 2004-03-04 | Bayer Ag | 5-Nitrobenzofurane |
US20050004194A1 (en) * | 2003-05-15 | 2005-01-06 | Graves Kurt Chum | Use of organic compounds |
US20060093673A1 (en) * | 2003-06-27 | 2006-05-04 | Coury Arthur J | Controlled release of anti-arrhythmic agents |
WO2005018635A2 (en) * | 2003-08-07 | 2005-03-03 | Cardiome Pharma Corp. | Ion channel modulating activity i |
US7820702B2 (en) * | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US20050182105A1 (en) * | 2004-02-04 | 2005-08-18 | Nirschl Alexandra A. | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function |
US7772232B2 (en) * | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
FR2875409B1 (fr) * | 2004-09-17 | 2010-05-07 | Sanofi Aventis | Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose |
GB0611210D0 (en) * | 2006-06-07 | 2006-07-19 | Cambrex Karlskoga Ab | Process |
DE102006035912A1 (de) * | 2006-07-31 | 2008-02-07 | Südzucker AG Mannheim/Ochsenfurt | Verwendung von Isomaltulose in regenerativ wirkenden Nahrungsmitteln |
US20090076137A1 (en) * | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched dronedarone |
FR2930149B1 (fr) * | 2008-04-17 | 2011-02-18 | Sanofi Aventis | Association de dronedarone avec au moins un diuretique, son application en therapeutique |
EP2280701A2 (en) * | 2008-04-17 | 2011-02-09 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
FR2930150B1 (fr) * | 2008-06-24 | 2011-01-14 | Sanofi Aventis | Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang |
EP2133075A1 (en) * | 2008-06-10 | 2009-12-16 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament intended for the prevention of cardioversion |
EP2133074A1 (en) * | 2008-06-10 | 2009-12-16 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation |
EP2153830A1 (en) * | 2008-08-07 | 2010-02-17 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament intended for the prevention of stroke or transient ischemic attack |
-
2008
- 2008-04-29 EP EP08290407A patent/EP2116239A1/en not_active Withdrawn
-
2009
- 2009-04-27 AR ARP090101485A patent/AR072954A1/es not_active Application Discontinuation
- 2009-04-28 AU AU2009241286A patent/AU2009241286A1/en not_active Abandoned
- 2009-04-28 MX MX2010011873A patent/MX2010011873A/es not_active Application Discontinuation
- 2009-04-28 BR BRPI0912706A patent/BRPI0912706A2/pt not_active IP Right Cessation
- 2009-04-28 JP JP2011506799A patent/JP2011518872A/ja active Pending
- 2009-04-28 CL CL2009001018A patent/CL2009001018A1/es unknown
- 2009-04-28 CN CN2009801248266A patent/CN102076337A/zh active Pending
- 2009-04-28 EP EP09738483A patent/EP2291183A2/en not_active Withdrawn
- 2009-04-28 NZ NZ588886A patent/NZ588886A/xx not_active IP Right Cessation
- 2009-04-28 CA CA2722815A patent/CA2722815A1/en not_active Abandoned
- 2009-04-28 EA EA201071138A patent/EA201071138A1/ru unknown
- 2009-04-28 WO PCT/IB2009/005930 patent/WO2009133470A2/en active Application Filing
- 2009-04-28 UA UAA201012809A patent/UA100883C2/ru unknown
- 2009-04-28 SG SG2013013537A patent/SG188180A1/en unknown
- 2009-04-28 KR KR1020107024051A patent/KR20100135853A/ko not_active Application Discontinuation
- 2009-04-28 PE PE2009000576A patent/PE20091885A1/es not_active Application Discontinuation
- 2009-04-29 TW TW098114259A patent/TW200948355A/zh unknown
- 2009-04-29 PA PA20098824601A patent/PA8824601A1/es unknown
- 2009-04-29 UY UY0001031790A patent/UY31790A/es not_active Application Discontinuation
- 2009-04-29 US US12/431,830 patent/US20100016423A1/en not_active Abandoned
-
2010
- 2010-10-24 IL IL208900A patent/IL208900A0/en unknown
- 2010-10-26 EC EC2010010567A patent/ECSP10010567A/es unknown
- 2010-10-27 NI NI201000181A patent/NI201000181A/es unknown
- 2010-10-28 DO DO2010000327A patent/DOP2010000327A/es unknown
- 2010-10-28 CO CO10133915A patent/CO6311076A2/es not_active Application Discontinuation
- 2010-10-28 ZA ZA2010/07727A patent/ZA201007727B/en unknown
- 2010-11-11 MA MA33340A patent/MA32299B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
JP2011518872A (ja) | 2011-06-30 |
NI201000181A (es) | 2012-03-15 |
KR20100135853A (ko) | 2010-12-27 |
PE20091885A1 (es) | 2009-12-31 |
UY31790A (es) | 2009-12-14 |
ECSP10010567A (es) | 2010-11-30 |
MA32299B1 (fr) | 2011-05-02 |
PA8824601A1 (es) | 2009-12-16 |
EP2116239A1 (en) | 2009-11-11 |
IL208900A0 (en) | 2011-01-31 |
CL2009001018A1 (es) | 2011-01-07 |
EA201071138A1 (ru) | 2011-06-30 |
UA100883C2 (ru) | 2013-02-11 |
CA2722815A1 (en) | 2009-11-05 |
WO2009133470A2 (en) | 2009-11-05 |
US20100016423A1 (en) | 2010-01-21 |
WO2009133470A3 (en) | 2009-12-23 |
NZ588886A (en) | 2013-01-25 |
AU2009241286A1 (en) | 2009-11-05 |
ZA201007727B (en) | 2013-01-30 |
CN102076337A (zh) | 2011-05-25 |
AR072954A1 (es) | 2010-10-06 |
BRPI0912706A2 (pt) | 2017-06-13 |
CO6311076A2 (es) | 2011-08-22 |
EP2291183A2 (en) | 2011-03-09 |
MX2010011873A (es) | 2011-04-05 |
SG188180A1 (en) | 2013-03-28 |
TW200948355A (en) | 2009-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120832T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
SV2017005489A (es) | Terapias de combinación para el tratamiento de cánceres | |
CL2015000294A1 (es) | Combinaciones farmaceuticas que comprenden un inhibidor de b-raf, un inhibidor del receptor del factor de crecimiento epidermico y opcionalmente un inhibidor pi3halpha y uso en el tratamiento de una enfermedad proliferativa. | |
IT1400982B1 (it) | Collirio osmotico trans-epiteliale per la cura del cheratocono. | |
CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
EA201500934A1 (ru) | Кардио- и нефропротективная противодиабетическая терапия | |
NI201400111A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
CO6480932A2 (es) | Antagonistas de la trayectoria hedgehog de ftalazina disustituida. | |
CR20110596A (es) | Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas | |
DOP2010000327A (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento de nivel de creatinina debido a la administracion de dronedarona | |
CL2019001214A1 (es) | Composición farmacéutica, métodos para tratamiento y sus usos. | |
ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
CL2015001180A1 (es) | Combinacion farmaceutica que comprende un copolimero de carboximetilcelulosa sodica con un grado de sustitucion de 0,35 a 0,80 y gosipol o un medicamento para el tratamiento de trastornos cognitivos seleccionado de neurolepticos, antidepresivos, anticonvulsivos o una combinacion de los mismos. | |
ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
ES2616035T3 (es) | Preparación para su uso en la profilaxis y el tratamiento de osteoporosis atípica | |
EA201071412A1 (ru) | Дронедарон для предотвращения кардиоверсии | |
AR082501A1 (es) | Usos terapeuticos de 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina | |
CO6480929A2 (es) | Procedimiento de uso del factor liberador de corticotropina para el tratamiento del cancer | |
AR085399A1 (es) | Combinacion antitumoral que comprende cabazitaxel y cisplatino | |
AR084435A1 (es) | Combinacion y composicion para el tratamiento de obesidad | |
UY32985A (es) | Uso de celivarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de celivarona | |
CL2009001221A1 (es) | Uso de un androgeno y/o un modulador selectivo del receptor de androgeno para preparar un medicamento para el tratamiento de la insuficiencia cardiaca o para retardar o detener el avance de la insuficiencia cardiaca en un sujeto humano de sexo femenino. | |
CR11745A (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatina debido a la administracion de dronedarona | |
AR103188A1 (es) | Formulaciones de paracetamol inyectables | |
CL2016000542A1 (es) | Composición que comprende hidroxipropil quitosano junto con excipientes y/o adyuvantes farmacéuticamente aceptables; útil en el tratamiento de la onicomicosis. |